Acute Intraocular Inflammation after Intravitreous Injections of Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Ophthalmology

Volumn 115, Issue 11, 2008, Pages

  Wickremasinghe, Sanjeewa S ^a   Michalova, Kira ^a,b   Gilhotra, Jagjit ^c   Guymer, Robyn H ^a,b   Harper, C Alex ^a,b   Wong, Tien Y ^a,b,d   Qureshi, Salmaan ^a,b  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHLORAMPHENICOL; STEROID;

AGED; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EYE INFLAMMATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 54949136462     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.05.007     Document Type: Article

References (20)

1. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
2. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
3. Rosenfeld P.J. Intravitreal Avastin: the low cost alternative to Lucentis?. Am J Ophthalmol 142 (2006) 141-143
4. Wong T.Y., Liew G., and Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 370 (2007) 204-206
5. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
6. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
7. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
8. Chen C.Y., Wong T.Y., and Heriot W.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 143 (2007) 510-512
9. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
10. Pieramici D.J., Avery R.L., Castellarin A.A., et al. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 26 (2006) 841-842
11. Aggio F.B., Farah M.E., de Melo G.B., et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 21 (2007) 408-409
12. United States Pharmacopeia-National Formulary. Pharmacopeial Forum. General Chapter 797: Pharmaceutical Compounding-Sterile Preparations (2008) 1-61. http://www.usp.org/pdf/EN/USPNF/generalChapter797.pdf Accessed February 24, 2008.
13. Aiello L.P., Brucker A.J., Chang S., et al. Evolving guidelines for intravitreous injections. Retina 24 suppl (2004) S3-S19
14. Wu L., Martinez-Castellanos M.A., Quiroz-Mercado H., et al., Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246 (2008) 81-87
15. Mamalis N., Edelhauser H.F., Dawson D.G., et al. Toxic anterior segment syndrome. J Cataract Refract Surg 32 (2006) 324-333
16. Remick D.G., Kunkel R.G., Larrick J.W., and Kunkel S.L. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 56 (1987) 583-590
17. Foster C.S., Monroe J.G., Campbell R., et al. Ocular immune responses. II. Priming of A/J mice in the vitreous induces either enhancement of or suppression of subsequent hapten-specific DTH responses. J Immunol 136 (1986) 2787-2791
18. Genentech, Inc. Avastin (bevacizumab): regional final label. BL125085/145 amendment (2008), Genentech, San Francisco, CA 43. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf Accessed February 24, 2008
19. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 17 suppl (1997) S15-S21
20. Koren E., Zuckerman L.A., and Mire-Sluis A.R. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr Pharm Biotechnol 3 (2002) 349-360